Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
第三届董事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of 福安药业（集团）股份有限公司 on April 25, 2016. It includes approvals of various reports such as the 2015 annual board work report, general manager work report, financial statements, audit report, internal control evaluation report, profit distribution plan, and fundraising usage report. It also mentions submission of these reports to the 2015 annual shareholders meeting for approval. The document contains voting results for each resolution and references to where the full reports are published on the China Securities Regulatory Commission designated disclosure website. The document is not the reports themselves but an official announcement of the board meeting decisions and resolutions, including the call for the 2015 annual shareholders meeting. The length is about 5805 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a formal regulatory announcement of board meeting resolutions and related procedural matters, not the full annual report or audit report itself.
2016-04-25 Chinese
国都证券股份有限公司关于公司发行股份购买资产2015年度业绩承诺实现情况之核查意见
Audit Report / Information Classification · 95% confidence The document is a report from an independent financial advisor (国都证券股份有限公司) regarding the 2015 performance commitment realization of 福安药业（集团）股份有限公司 related to an asset purchase transaction. It includes detailed information about profit commitments, compensation arrangements, impairment testing, and the actual performance results verified by an audit firm. The document is a formal verification and opinion on the fulfillment of profit commitments tied to a major asset acquisition, which is typical of an audit or verification report related to a specific transaction rather than a full annual report or earnings release. It is not a brief announcement or a presentation, but a detailed standalone report focused on audit and verification of financial performance commitments. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length is 3413 characters, which is sufficient for a detailed report but not a full annual report. No indication that this is a mere announcement or certification letter, so it is not RNS or RPA. FY 2015
2016-04-25 Chinese
关于举行2015年度网上业绩说明会的通知
AGM Information Classification · 95% confidence The document is a notice about holding the 2015 annual performance online briefing by the company 福安药业（集团）股份有限公司. It mentions the 2015 annual report has been published on the official disclosure website and invites investors to participate in the online performance explanation meeting. The document is short (566 characters) and serves as an announcement for an event related to the annual report, not the report itself. Therefore, it fits the category of AGM Information (AGM-R) as it relates to the annual general meeting or performance briefing event.
2016-04-25 Chinese
2015年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the fiscal year 2015 by 福安药业（集团）股份有限公司. It details the proposed cash dividend per share and the total amount to be distributed to shareholders. It mentions approval by the board and supervisory committee and that it will be submitted to the shareholders' meeting for approval. The document is short (595 characters) and focuses on dividend distribution details rather than full financial statements or comprehensive annual results. This fits the definition of a Notice of Dividend Amount (DIV) rather than a full Annual Report or Earnings Release.
2016-04-25 Chinese
2015年度控股股东及其他关联方占用资金情况专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (special audit report) concerning the 2015 year-end situation of funds occupied by controlling shareholders and other related parties of 福安药业（集团）股份有限公司. It is issued by an accounting firm and references the audit of the 2015 financial statements, including balance sheets and profit statements. The document includes a detailed summary table of funds occupied by related parties and states it is prepared according to regulatory requirements from the China Securities Regulatory Commission and the State-owned Assets Supervision and Administration Commission. The document is a standalone audit report focusing on a specific issue (related party fund occupation) and is not the full annual report (10-K) or a general audit report of the entire financial statements. It is also not an announcement or certification but a detailed audit report on a specific matter. Therefore, it fits the category of Audit Report / Information (AR). The document length is 2207 characters, which is consistent with a detailed audit report rather than a brief announcement or certification. FY 2015
2016-04-25 Chinese
2016年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 First Quarter Report" of 福安药业（集团）股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as revenue, net profit, cash flow, asset and liability changes, shareholder information, risk disclosures, and management discussion and analysis. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data and analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2016
2016-04-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.